-
Sanofi/Regeneron PD-1 inhibitor approved by FDA for first-line treatment of non-small cell lung cancer
Time of Update: 2021-03-24
Today, Sanofi and Regeneron jointly announced that the US FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of PD-L1 high expression (tumor ratio score ≥50%) Patients with advanced non-small cell lung cancer (NSCLC).
com/news-release/2021/02/22/2179862/0/en/FDA-approves-Libtayo-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-small-cell-lung -cancer-with-PD-L1-expression-of-50.
-
The FDA granted 5808 orphan drug approvals for 38 years after the implementation of the "Orphan Drug Act"
Time of Update: 2021-03-24
In order to change this situation, President Ronald Reagan signed the "Orphan Drug Act" on January 4, 1983, which aims to encourage the development of drugs and treatments for rare diseases and formulate the impact on the pharmaceutical industry.
-
The clinical application of Boan Bio-Navulumab injection was accepted
Time of Update: 2021-03-24
Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.
As the world's first PD-1 immune checkpoint inhibitor approved by regulatory agencies, nivolumab injection has become an important choice for the treatment of a variety of tumors, and has been approved for more than a dozen indications worldwide.
-
The doctors will prepare for them when they return home!
Time of Update: 2021-03-24
On January 25, at the press conference of the two sessions of Hubei Province, it was clearly stated that all township hospitals, community service centers and other grassroots medical and health institutions will set up a large number of empty staff, and it is planned to recruit 10,000 professional health professionals.
-
From now on, 119 new drugs will be reimbursable for health insurance
Time of Update: 2021-03-24
At the same time, for drugs successfully negotiated by the state, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, in order to further reduce the burden of medical expenses of the masses and facilitate the outpatient treatment of the masses, this city refers to the medical insurance outpatient clinics for urban employees and urban and rural residents.
-
2020 Oncology New Drug Data Card-Inituzumab
Time of Update: 2021-03-24
The data show that initumumab combined with vinorelbine In the treatment of HER2-positive metastatic breast cancer patients who have received one or more chemotherapy regimens in the past, compared with vinorelbine can significantly prolong the median PFS of the primary endpoint (39.
-
How does the number and scale of public hospitals develop? The Health and Wellness Commission replied!
Time of Update: 2021-03-24
According to the "Reply", the National Health Commission is studying and revising the national medical and health service system plan, scientifically determining the number, scale and layout of public hospitals and social hospitals, rationally adjusting the bed allocation standards of public hospitals, and supporting some powerful public hospitals On the basis of controlling the size of the single unit, appropriate construction and development of multiple hospitals, and rapid conversion of functions when a major epidemic occurs.
-
Yuandong's new injection products are coming!
Time of Update: 2021-03-24
Figure 1: Registration status of Yuandong's Phenylephrine Hydrochloride Injection Source: CDE official website Figure 2: Overall sales of phenylephrine hydrochloride injection Source: Comprehensive compilation of Minet's database At present, only Shanghai Hefeng Pharmaceutical has obtained approval for phenylephrine hydrochloride injection on the domestic market, and no company has reviewed it yet .
-
Yuandong Bio-Caffeine Citrate Injection Passes the Consistency Evaluation of Injection Quality and Efficacy
Time of Update: 2021-03-24
On April 19, 2019, the application for consistency evaluation of caffeine citrate injection submitted by the company to the State Food and Drug Administration was accepted.
-
INOVIO announces the administration of the first subject of Lassa fever vaccine
Time of Update: 2021-03-24
INOVIO announced today that the Phase 1B clinical trial of INO-4500 (its Lassa fever DNA vaccine candidate) in Ghana has completed the first subject administration.
-
Xianju Pharmaceutical: Received notification of acceptance of consistency evaluation of prednisone acetate tablets
Time of Update: 2021-03-24
They are commonly used, safe and effective drugs for the treatment of allergic and autoimmune inflammatory diseases.
The current product implementation standard is "Chinese Pharmacopoeia" 2020 edition two.
-
Global oncology drug giants ranked TOP10 in 2020
Time of Update: 2021-03-24
Tyvyt (sintilimab), which cooperates with Cinda, helps Lilly occupy a place in the field of tumor immunotherapy, achieving revenue of 309 million US dollars in 2020; LOXO Oncology, which has been heavily acquired, begins In return, Retevmo (RET inhibitor) gained US$37 million in half a year from the market, and the BTK C481S inhibitor LOXO-305 has also been advanced to phase III clinical trials, which is only one step away from the market.
-
From today, the implementation of 4 regulations affects all pharmaceutical workers
Time of Update: 2021-03-24
From March 1st, the supplementary provisions of the new criminal law, the 2020 drug catalogue, the management methods for the batch issuance of biological products, and the management methods for the clinical application of anti-tumor drugs have been implemented, affecting all pharmaceutical workers.
-
AstraZeneca Class 1 new drug approved in China for clinical development to treat breast cancer
Time of Update: 2021-03-24
It is expected that the clinical study of AstraZeneca is oral estrogen receptor degradation agent AZD9833 in China will proceed smoothly, bringing new treatment options to breast cancer patients.
-
Which varieties of proprietary Chinese medicines have been signaled or will be included first?
Time of Update: 2021-03-24
Medical Network News, February 24th, the signal of centralized procurement of Chinese patent medicines has come out. Which varieties may be included first? Popular varieties of Chinese patent medic
-
National revised norms for medical researchers and institutions: Do not step on the "red line"!
Time of Update: 2021-03-24
The third is to strengthen results management and establish a traceability mechanism for the entire process of scientific research results.
The third is to strengthen results management and establish a traceability mechanism for the entire process of scientific research results.
-
China urgently needs new drugs for overseas rare diseases: more than 10 models have been approved and multiple models have been submitted for marketing applications
Time of Update: 2021-03-24
Source: Guanlan PharmaceuticalClinically urgently needed overseas new drugs mainly refer to those that have been marketed in Europe, America and Japan in recent years but have not yet been marketed in China, and are used to treat rare diseases, severely life-threatening or severely affecting the quality of life, and there are no effective treatments or obvious clinical advantages.
-
Kangfang Bio/Zhengda Tianqing PD-1 first-line squamous NSCLC phase III clinical trial reached the primary endpoint
Time of Update: 2021-03-24
On February 24, Kangfang Biological and Sino Biopharmaceutical jointly announced that their jointly developed anti-PD-1 monoclonal antibody "Paimrizumab" combined with chemotherapy for the first-line treatment of advanced/metastatic squamous non-small cell lung cancer (NSCLC) The phase III clinical interim analysis reached the main research endpoint, and plans to communicate with CDE to submit the listing application.
-
Yang Jiafang reveals to you the various causes of repeated vitiligo
Time of Update: 2021-03-24
Failure to follow the doctor's instructions, some patients with vitiligo, usually busy with work and other external factors, forget to treat or stop the treatment when they get a little better, resulting in the skin color has not returned to normal, and the damaged melanocytes have not been completely repaired.
-
National Health And Wellness Commission: No contribution can not be named papers! Not tied to performance or bonuses
Time of Update: 2021-03-24
Within 1 month after the publication of relevant papers and other scientific research results , To submit the original information to the institution After the completion of the research, medical scientific research personnel shall follow the corresponding biosafety and scientific research management regulations for the storage, sharing and destruction of human or animal samples, toxic substances, data or materials.
